AZN: Year-To-Date and Q3 2017 Results Announcement

AstraZeneca PLC
9 November 2017 07:00

Year-To-Date and Q3 2017 Results
An improved sales performance as the pipeline-driven transformation gathered pace

Click on, or paste the following link into your web browser, to view the associated PDF document.

This information is provided by RNS
The company news service from the London Stock Exchange


About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: